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Prevalence of psychiatric co-morbidity 
in treatment-seeking problem 
gamblers: A systematic review and 
meta-analysis
Nicki A Dowling1,2,3,4, Sean Cowlishaw5, Alun C Jackson2, 
Stephanie S Merkouris1,6, Kate L Francis2 and  
Darren R Christensen2,7
Abstract
Objective: The aim of this paper was to systematically review and meta-analyse the prevalence of co-morbid psychiatric 
disorders (DSM-IV Axis I disorders) among treatment-seeking problem gamblers.
Methods: A systematic search was conducted for peer-reviewed studies that provided prevalence estimates of Axis I 
psychiatric disorders in individuals seeking psychological or pharmacological treatment for problem gambling (including 
pathological gambling). Meta-analytic techniques were performed to estimate the weighted mean effect size and hetero-
geneity across studies.
Results: Results from 36 studies identified high rates of co-morbid current (74.8%, 95% CI 36.5–93.9) and lifetime (75.5%, 
95% CI 46.5–91.8) Axis I disorders. There were high rates of current mood disorders (23.1%, 95% CI 14.9–34.0), alcohol 
use disorders (21.2%, 95% CI 15.6–28.1), anxiety disorders (17.6%, 95% CI 10.8–27.3) and substance (non-alcohol) use dis-
orders (7.0%, 95% CI 1.7–24.9). Specifically, the highest mean prevalence of current psychiatric disorders was for nicotine 
dependence (56.4%, 95% CI 35.7–75.2) and major depressive disorder (29.9%, 95% CI 20.5–41.3), with smaller estimates 
for alcohol abuse (18.2%, 95% CI 13.4–24.2), alcohol dependence (15.2%, 95% CI 10.2–22.0), social phobia (14.9%, 95% CI 
2.0–59.8), generalised anxiety disorder (14.4%, 95% CI 3.9–40.8), panic disorder (13.7%, 95% CI 6.7–26.0), post-traumatic 
stress disorder (12.3%, 95% CI 3.4–35.7), cannabis use disorder (11.5%, 95% CI 4.8–25.0), attention-deficit hyperactivity dis-
order (9.3%, 95% CI 4.1–19.6), adjustment disorder (9.2%, 95% CI 4.8–17.2), bipolar disorder (8.8%, 95% CI 4.4–17.1) and 
obsessive-compulsive disorder (8.2%, 95% CI 3.4–18.6). There were no consistent patterns according to gambling problem 
severity, type of treatment facility and study jurisdiction. Although these estimates were robust to the inclusion of studies 
with non-representative sampling biases, they should be interpreted with caution as they were highly variable across studies.
Conclusions: The findings highlight the need for gambling treatment services to undertake routine screening and 
assessment of psychiatric co-morbidity and provide treatment approaches that adequately manage these co-morbid 
disorders. Further research is required to explore the reasons for the variability observed in the prevalence estimates.
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The Diagnostic and Statistical Manual of Mental Disorders 
(Fifth Edition) (DSM-5) (American Psychiatric Association, 
2013) has reclassified pathological gambling as an addic-
tion and related disorder along with alcohol and substance 
use disorders, and renamed it gambling disorder. In many 
jurisdictions, however, the term problem gambling is 
employed to describe all forms of gambling, including the 
more severe classification of pathological gambling, that 
lead to adverse consequences for the gambler, others, or the 
community (Neal et al., 2005). There is substantial evi-
dence that problem gambling can result in many adverse 
consequences, including impaired mental and physical 
health, relationship and family dysfunction, financial prob-
lems, employment difficulties and legal issues (Productivity 
Commission, 1999). Problem gambling has also been con-
sistently associated with a range of co-morbid psychiatric 
conditions formerly known as Axis I disorders in the 
DSM-IV, including alcohol and other substance use disor-
ders, mood and anxiety disorders, and other impulse con-
trol disorders (Crockford and El-Guebaly, 1998; Lorains 
et al., 2011; Petry, 2005; Westphal and Johnson, 2007).
Internationally, the co-occurrence between problem 
gambling and co-morbid psychiatric conditions has been 
empirically examined in both epidemiological and clinical 
samples. By randomly sampling the general population, 
epidemiological studies provide results that are representa-
tive of problem gamblers in the community. They are, how-
ever, generally only able to determine the co-occurrence of 
problem gambling with highly prevalent co-morbid disor-
ders because they yield very small numbers of problem 
gamblers (Lorains et al., 2011; Westphal and Johnson, 
2007). A systematic review and meta-analysis of co-morbid 
disorders in population-representative samples of problem 
gamblers revealed high rates of psychiatric disorders, 
including nicotine dependence (60%), alcohol and sub-
stance use disorders (58%), mood disorders (38%) and 
anxiety disorders (37%) (Lorains et al., 2011).
Although these population-representative studies pro-
vide important information about the prevalence of co- 
morbidity in problem gamblers living in the community, 
caution is required in generalising results from these sam-
ples to treatment-seeking populations given emerging evi-
dence that treatment-seeking problem gamblers display 
more severe gambling problems and a greater variety and 
intensity of co-morbid psychiatric disorders compared with 
their non-treatment seeking counterparts (Crockford and 
El-Guebaly, 1998; Slutske et al., 2001; Specker et al., 1996). 
Although they generally employ non-random samples, 
treatment-seeking studies generally comprise larger sam-
ples of problem gamblers, which allows for the investiga-
tion of lower prevalence co-morbid disorders and an 
investigation of how the level of gambling severity co- 
varies with co-morbid disorders (Westphal and Johnson, 2007).
To date, only narrative reviews of psychiatric co-mor-
bidity in treatment-seeking problem gambling samples are 
available (Petry, 2005; Specker et al., 1996; Westphal and 
Johnson, 2007). Unfortunately, these reviews are not based 
on all of the available evidence, generally only explore the 
prevalence of high prevalence disorders, such as mood dis-
orders, anxiety disorders and substance use disorders, and 
are unable to explore the degree to which prevalence esti-
mates of co-morbidity fluctuate as a function of clinical and 
methodological considerations, such as gambling severity. 
They are also generally characterised by a lack of quality 
and risk of bias appraisal, a failure to identify the relative 
strength and reliability of the evidence for each of the psy-
chiatric co-morbid disorders, and a lack of clarity about the 
generalizability of the findings to all treatment-seeking 
problem gamblers. It is therefore important that a system-
atic review of psychiatric co-morbidity in treatment-seek-
ing problem gambling samples is conducted to redress the 
limitations of these narrative reviews.
The findings relating to psychiatric co-morbidity in treat-
ment-seeking samples of problem gamblers are important in 
understanding individual treatment needs and outcomes 
(Lorains et al., 2011). There is accumulating evidence that the 
presence of co-morbid disorders in treatment-seeking prob-
lem gamblers is associated with an increased severity of gam-
bling behaviour, gambling-related consequences, psychiatric 
symptoms, impulsivity and other psychosocial difficulties 
(Grall-Bronnec et al., 2011; Grant and Kim, 2003; Ibanez 
et al., 2001; Ledgerwood and Petry, 2006). The presence of 
co-morbid psychiatric conditions therefore has implications 
for individual case formulation, treatment planning and selec-
tion, the proposed objectives and expectations of the selected 
treatment, and the length of treatment. Psychiatric co-morbid-
ity may also affect an individual’s compliance with treatment, 
the success of treatment, the likelihood of relapse and the 
number of treatment attempts (Ibanez et al., 2001; Kausch, 
2003a; Kruedelbach et al., 2006; Westphal and Johnson, 
2007). Although there are equivocal findings, there is some 
evidence that problem gamblers with co-morbid psychiatric 
symptoms have poorer outcomes and higher rates of drop-out 
for psychological interventions than those without co-morbid 
disorders (Echeburua et al., 2001; Hodgins and El-Guebaly, 
2010; Milton et al., 2002).
The findings from both community-representative and 
treatment-seeking studies suggest that prevalence estimates 
of psychiatric co-morbidity in treatment-seeking problem 
gamblers vary widely. There is therefore a need to explore the 
methodological and clinical factors that may explain these 
variations in estimates. The heterogeneity in prevalence esti-
mates may be due to differences in the characteristics of the 
sample or patient population, measurement factors, treatment 
factors or methodological considerations (Bagby et al., 2008; 
Blaszczynski and Steel, 1998; Echeburua and Fernandez-
Montalvo, 2008; Lorains et al., 2011). There is some evidence 
that pathological gamblers display higher rates of co-morbidity 
than problem gamblers (Lorains et al., 2011) and that self-
report inventories generally produce higher rates of 
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co-morbidity than clinical interviews (Jimenez-Murcia et al., 
2009; Kruedelbach et al., 2006). There is also some indication 
that gamblers attending residential services report higher 
rates of co-morbid conditions than those attending outpatient 
services (Battersby et al., 2006; Ladouceur et al., 2006; Petry, 
2005) and that rates may be affected by region (Lorains et al., 
2011; Specker et al., 1996).
Aims
The aims of the current paper are to: (1) evaluate the preva-
lence of current and lifetime co-morbid psychiatric disor-
ders that are listed as Axis I diagnoses in the fourth edition 
of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV) (American Psychiatric Association, 
2000) among problem gamblers seeking treatment using 
meta-analytic techniques; (2) explore the factors that 
explain the variability in the prevalence estimates of these 
co-morbid conditions using sub-group analyses; and (3) 
examine whether findings were robust to the quality of the 
study methodologies using sensitivity analyses. Prevalence 
estimates of co-morbid disorders that are listed as Axis II 
diagnoses (personality disorders) in the DSM-IV are 
reported in a separate article (Dowling et al., 2014a).
Method
The methodology employed in this review is compliant 
with the Preferred Reporting Items for Systematic reviews 
and Meta-Analyses (PRISMA) (Moher et al., 2009) and the 
guidelines for the Meta-analysis Of Observational Studies 
in Epidemiology (MOOSE) (Stroup et al., 2000).
Search strategy
A systematic search was conducted for studies that pro-
vided prevalence estimates of psychiatric disorders in indi-
viduals seeking psychological or pharmacological treatment 
for problem gambling. This search procedure comprised a 
number of strategies. Electronic databases, including 
Medline, PsycInfo, EMBASE and CINAHL, were searched. 
A number of specific journals that were not indexed in the 
electronic databases were also manually examined. These 
included Gambling Research (2003 onwards), International 
Gambling Studies (2001–2003) and Journal of Gambling 
Issues (2000–2006). Finally, the reference lists of all 
included studies and several narrative reviews were also 
searched manually. The search was limited to peer-reviewed 
published studies so as to ensure a rigorous methodological 
standard of included research. The search terms used incor-
porated a combination of keywords and wildcards relating 
to problem gambling and treatment. It did not include key-
words relating to specific co-morbid psychiatric conditions. 
The search was restricted to articles published from January 
1990 to August 2011, consistent with the development of 
the first standardised and validated assessment instrument 
for the identification of problem gambling in clinical set-
tings (Lesieur and Blume, 1987). A detailed description of 
the search strategy is provided in Appendix A.
Inclusion criteria
Studies were considered eligible for the current review if 
they met the following inclusion criteria: (1) the study sam-
ple comprised adults recruited from treatment services 
where problem gambling was the index condition or clini-
cal trials of gambling treatment for problem gamblers 
recruited from these services or the community. Gambling 
treatment included any treatment primarily delivered for 
the index condition of problem gambling, including psy-
chological treatments (including self-help and Gamblers 
Anonymous) or pharmacological treatments. These treat-
ments could be delivered in any setting, including specialist 
gambling services, addiction services, impulse control dis-
orders services or mental health services. They could be 
delivered in any modality, including outpatient, residential, 
online or telephone; (2) the study provided an estimate of 
the prevalence of one or more psychiatric conditions that 
are listed as diagnoses in the DSM-IV identified using 
standardised and validated self-report measures with clini-
cal cut-off scores or clinical interviews based on the 
DSM-IV or previous versions of the DSM; (3) the full-text 
report was available in English; and (4) the study was 
reported in a complete manuscript outlining original work 
published in a peer-reviewed journal from 1990 to 2011.
Studies were not eligible if they: (1) applied inclusion or 
exclusion criteria (for participant admission to the study) 
based on DSM-IV diagnostic conditions (e.g. a clinical trial 
that excluded participants on the basis of all current Axis I 
disorders). Studies that excluded participants on the basis 
of conditions that preclude completion of assessment meas-
ures or treatment (e.g. cognitive impairment, such as intel-
lectual disability, delirium, dementia or amnesia; or acute/
uncontrolled psychiatric disorders, such as psychotic disor-
der or suicidality) were included; (2) assessed clinical char-
acteristics that are not listed as diagnostic conditions in the 
DSM-IV (e.g. impulsivity, suicidality, personality traits, 
substance use, sensation seeking); or (3) failed to provide 
sufficient data (e.g. providing only means or standard devi-
ations, combining prevalence estimates for multiple co-
morbid disorders, or failing to identify the measure 
employed). Where there were multiple articles based on the 
same sample: (a) only the study with the larger sample was 
included when a larger sample in one study subsumed a 
smaller sample in another study; (b) only the study with the 
most focus on co-morbid disorders was reported when two 
studies reported the same prevalence data from the same 
sample; and (c) both studies were included and are listed 
together in the table of included studies (Table 1) when two 
studies with the same sample reported prevalence data for 
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different disorders. Data from each sample was included 
only once in any given analysis.
Search results
A PRISMA flow diagram of the search results is displayed 
in Figure 1. The search identified 3,587 articles after dupli-
cate records were removed. The title and abstracts of these 
records were independently reviewed for inclusion by two 
separate authors. The full-texts of the 257 articles that were 
deemed potentially eligible were retrieved and 42 studies, 
published in 46 articles, met the inclusion criteria. Of these, 
36 studies, published in 39 articles, provided prevalence 
estimates for DSM-IV Axis I disorders and are reported in 
this article. Fifteen studies, published in 16 articles, pro-
vided prevalence estimates for Axis II disorders (personal-
ity disorders) and are reported separately (Dowling et al., 
2014a).
Data extraction
The first author (ND) extracted data from the included 
studies. In most cases, the prevalence estimate was availa-
ble from the primary study. In other instances, it was neces-
sary to combine findings reported for separate groups (e.g. 
men and women) to derive total sample prevalence rates. 
Prevalence estimates were reported for co-morbid psychi-
atric disorders that had three or more estimates available. 
Figure 1. Flow diagram of search results.
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To ensure the data extraction was accurate, one-third of the 
articles (33%; k=15) were randomly selected for double 
data extraction by two independent reviewers (AJ and KF). 
The inter-rater agreement across the multiple reviewers 
was 98.2%. Discrepancies were resolved through group 
discussion with third reviewer as arbiter.
Data analysis
Meta-analyses. Findings from primary studies were synthe-
sised in meta-analyses using the Comprehensive Meta-
Analysis (CMA) program (Version 2.0) (Borenstein et al., 
2009). A series of separate meta-analyses were conducted 
to provide the current best prevalence estimate of each co-
morbid disorder, all using a ‘random effects’ model. When 
differences across studies are attributed mainly to sampling 
error, a random-effects analysis provides an estimate of the 
weighted mean effect and a 95% confidence interval (CI) 
(that indicates the precision of this estimate). The I2 statistic 
indicates the amount of variation across studies due to true 
differences (heterogeneity) rather than chance (sampling 
error), and is expressed as a proportion (%) of the total 
observed variance. This statistic is in the range of 0–100%, 
whereby values of 25%, 50% and 75% are tentatively sug-
gested to represent low, moderate and high levels of hetero-
geneity, respectively (Higgins et al., 2003).
Subgroup analyses. The observation of heterogeneity across 
studies precipitated consideration of study characteristics 
that could explain these between-study differences. Sub-
group analyses were conducted to examine potential 
sources of heterogeneity for co-morbid disorders that had a 
sufficient number of primary studies available (10 or more). 
This involved the production of separate estimates of sum-
mary effect (with 95% CIs) for subgroups of studies. Sig-
nificant differences were assumed when the 95% CIs did 
not overlap (Hunter and Schmidt, 2004). Based on previous 
literature, several study characteristics potentially explain-
ing the observed variance were identified before the com-
mencement of analysis. These were: (1) gambling problem 
severity (pathological gamblers compared to problem gam-
blers); (2) the measure of co-morbidity employed (clini-
cian-administered interviews compared to self-report 
questionnaires); (3) the type of treatment facility (outpa-
tient treatment services only compared to residential treat-
ment services only); and (4) the jurisdiction in which the 
study was conducted (treatment services located in the US 
compared to treatment services located in Europe); other 
jurisdictions were not included in the subgroup analyses 
due to an insufficient number of studies.
Risk of bias assessment. The use of quality scoring in meta-
analyses of observational studies is controversial and gen-
erally not recommended (Higgins et al., 2003; Stroup et al., 
2000; Viswanathan et al., 2012) because scores constructed 
in an ad hoc fashion may lack demonstrated validity, and 
results may not be associated with quality (Jüni et al., 
1999). A components approach was therefore adopted to 
assess risk of bias in this systematic review, whereby each 
study was rated on individual criteria that reflect the meth-
odological risk of bias (Higgins et al., 2003; Viswanathan 
et al., 2012). These criteria explicitly evaluated risk of 
selection bias (use of an appropriate comparison group, 
volunteer/selection bias, and observation of treatment in 
naturalistic settings settings), performance bias (concurrent 
treatment restriction), detection bias (valid and reliable 
gambling measure) and reporting biases (industry sponsor-
ship) (Higgins et al., 2003; Viswanathan et al., 2012). Stud-
ies that failed to consecutively or randomly recruit 
participants and/or were clinical trials were classified as 
having a non-representative sampling bias. With a view to 
contextualising this information, studies were also exam-
ined for the degree to which the measurement of co-mor-
bidity was the stated purpose of the study. These criteria 
were reviewed by pairs of bias reviewers with a third 
reviewer serving as arbiter of conflicts. The inter-rater 
agreement across the multiple reviewers for the assessment 
of bias criteria was 95.1%.
Sensitivity analyses. As recommended by experts in the area 
of risk of bias assessment (Stroup et al., 2000; Viswanathan 
et al., 2012), sensitivity analyses were conducted to exam-
ine whether findings were robust to the quality of the meth-
odological approaches of the included studies. The 
sensitivity analyses were sequentially limited to studies 
with representative samples: (1) observational studies of 
treatment in naturalistic settings (versus clinical trials 
which were excluded); and (2) random samples or recruit-
ment of consecutive admissions (versus convenience sam-
ples comprising research participants who have volunteered 
to participate [self-selected samples] or studies failing to 
indicate the sampling strategies which were excluded). The 
data analytic approach employed in this study for each sen-
sitivity analysis, whereby the meta-analysis was under-
taken twice: first, including all studies and second, only 
including those that are definitely known to be eligible, is 
recommended by the Cochrane collaboration (Higgins and 
Green, 2011). These analyses were conducted for all types 
of co-morbidity, irrespective of number of studies.
Study and sample characteristics
The characteristics of the included studies reporting preva-
lence estimates for DSM-IV Axis I disorders are presented 
in Table 1. The sizes of the samples were in the range of 
14–592 (M=145.1, SD=143.4, median=100). The average 
age of study participants was in the range of 33.2–64.9 
years (M=43.0, SD=6.7, median=44) and the proportion of 
men in the samples was in the range of 42–100% (M=62.5%, 
SD=18.9, median=69). Most samples were restricted to 
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pathological gamblers only (77.8%) measured via diagnos-
tic criteria (69.4%) who were treated in gambling services 
(88.9%). Most samples were recruited from the US (44.4%) 
and Europe (25.0%) and most studies (94.4%) were pub-
lished between 2001 and 2011. Co-morbidity measures 
were predominantly clinician-administered interviews 
(88.9%), with few studies using self-report measures 
(11.1%). Less commonly reported data were the problem-
atic gambling activity (47.2% mixed, 2.8% electronic gam-
ing machines only, 50.0% not reported), the type of 
treatment facility (52.8% outpatient facilities, 13.9% resi-
dential facilities, 11.1% recruitment from multiple types of 
facilities, 22.2% not reported), and the type of treatment 
delivered (33.3% psychological treatments, 8.3% com-
bined treatments, 11.1% recruitment from multiple types of 
treatments, 47.2% not reported).
Approximately one-third of studies (k=11, 30.6%) indi-
cated they excluded participants who were unable to com-
plete assessment measures or treatment. However, with the 
exception of one study that excluded 23 participants on the 
basis of an ‘unstable mental state’ (Smith et al., 2010), these 
studies either failed to report the number of participants 
excluded on this basis (k=8) or reported that few (none or 
one) participants were excluded on this basis (k=2). A series 
of subgroup analyses revealed that there were no signifi-
cant differences in prevalence estimates between studies 
that excluded participants on this basis and those that 
did not.
Results
Meta-analyses
Current DSM-IV Axis I disorders. Prevalence estimates for 
any current DSM-IV Axis I disorder were provided by five 
studies (Table 2). There was a weighted mean effect of 
74.8% (95% CI 36.5–93.9) with very high between-study 
heterogeneity.
Substance use disorders. Prevalence estimates for sub-
stance use disorders were provided by 26 studies (Table 3). 
There were weighted mean effects of 22.2% (95% CI 36.5–
93.9) for any alcohol or substance use disorder, 21.2% 
(95% CI 5.6–28.1) for any alcohol use disorder and 7.0% 
(95% CI 1.7–24.9) for any substance (non-alcohol) use dis-
order. Specifically, the highest weighted mean effect was 
for nicotine dependence (56.4%, 95% CI 35.7–75.2) fol-
lowed by alcohol abuse (18.2%, 95% CI 13.4–24.2), alco-
hol dependence (15.2%, 95% CI 10.2–22.0) and cannabis 
use disorder (11.5%, 95% CI 4.8–25.0). There was moder-
ate to very high between-study heterogeneity for current 
substance use disorders.
Mood disorders. Prevalence estimates for mood disor-
ders were provided by 22 studies (Table 4). There was a 
weighted mean effect of 23.1% (95% CI 14.9–34.0) for 
any mood disorder. Specifically, there were weighted mean 
effects of 29.9% (95% CI 20.5–41.3) for major depressive 
disorder, 8.8% (95% CI 4.4–17.1) for bipolar disorder and 
6.7% (95% CI 4.8–9.2) for dysthymic disorder. There was 
high between-study heterogeneity for all current mood 
disorders, except dysthymic disorder, which had very low 
between-study heterogeneity.
Anxiety disorders. Prevalence estimates for anxiety dis-
orders were provided by 15 studies (Table 5). There was a 
weighted mean effect of 17.6% (95% CI 0.8–27.3) for any 
anxiety disorder. The anxiety disorders with the highest 
weighted mean effects were social phobia (14.9%, 95% CI 
2.0–59.8) and generalised anxiety disorder (GAD) (14.4%, 
95% CI 3.9–40.8), followed by panic disorder (13.7%, 95% 
CI 6.7–26.0), post-traumatic stress disorder (PTSD) (12.3%, 
95% CI 3.4–35.7) and obsessive-compulsive disorder (OCD) 
(8.2%, 95% CI 3.4–18.6). There was high to very high 
between-study heterogeneity for current anxiety disorders.
Other disorders. Prevalence estimates for other DSM-IV 
Axis I disorders were provided by 13 studies (Table 6). None 
of the primary articles employed to derive the prevalence 
Table 2. Prevalence of any current Axis I disorder in treatment-seeking problem gamblers.
Study Co-morbidity measure Any current Axis I disorder
Grant and Potenza (2006b) SCID (DSM-IV) 21.0%
Kausch (2004) Clinical diagnosis 93.0%
Patterson et al. (2006) MINI 100%
Tavares and Gentil (2007) SCAN 81.0%
Specker et al. (1996) SCID (DSM-III-R) 54.0%
Summary effect (95% CI) 74.8% (36.5–93.9)
I2 (%) 95.88
MINI: Mini International Neuropsychiatric Interview; SCAN: Schedules for Clinical Assessment in Neuropsychiatry; SCID (DSM-III-R): Structured 
Clinical Interview for DSM-III-R; SCID (DSM-IV): Structured Clinical Interview for DSM-IV.
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estimate for psychotic disorder reported excluding partici-
pants on the basis of conditions that precluded completion 
of assessment measures or treatment. The highest weighted 
mean effects were for attention-deficit hyperactivity disor-
der (ADHD) (9.3%, 95% CI 4.1–19.6) and adjustment dis-
order (9.2%, 95% CI 4.8–17.2). There was low to very low 
between-study heterogeneity for all current other disorders, 
except adjustment disorder and ADHD, which had moder-
ate to high between-study heterogeneity.
Lifetime DSM-IV Axis I disorders. Prevalence estimates for 
lifetime DSM-IV Axis I disorders were provided by 13 
Table 4. Prevalence of co-morbid current mood disorders in treatment-seeking problem gamblers.
Study
Co-morbidity 
measure
Any mood 
disorder
Major depressive 
disorder
Dysthymic 
disorder Bipolar disorder
Battersby et al. (2006) BDI 48.8%  
Dannon et al. (2006) Clinical diagnosis 11.5% 3.8%
Goudriaan et al. (2010) CIDI 17.0%  
Grant and Grosz (2004) Clinical diagnosis 42.9%  
Grant and Kim (2002) Clinical diagnosis 28.0% 6.0%
Grant and Kim (2008) SCID (DSM-IV) 10.4% 4.2%
Grant et al. (2008) SCID (DSM-IV) 29.5% 13.1% 6.7%  
Grant and Potenza (2006b) SCID (DSM-IV) 4.8%  
Ibanez et al. (2001) SCID (DSM-III-R) 8.7%  
Jimenez-Murcia et al. (2009) Clinical diagnosis 
(DSM-IV)
12.1%  
Kausch (2003a)/Kausch (2003b) Clinical diagnosis 42.5% 7.1%
Kennedy et al. (2005) Clinical diagnosis 25.7%  
Kerber et al. (2008) MINI 82.5% 82.5% 20.0%
Kroeber (1992) Clinical diagnosis 
(DSM-III-R)
11.6% 4.7%
Lee et al. (2011) SCID (DSM-IV) 11.7%  
Patterson et al. (2006) MINI 83.0% 16.7% 5.6% 66.6%
Sander and Peters (2009) Clinical diagnosis 
(DSM-IV/ICD-10)
18.5% 17.5%  
Specker et al. (1996) SCID (DSM-III-R) 37.5% 35.0% 7.5% 0%
Stinchfield and Winters (2001) Clinical diagnosis 
(DSM-III-R)
12.0%  
Tavares and Gentil (2007) SCAN 45.0% 7.5%
Tavares et al. (2003) SCAN 71.4% 7.9%
Zimmerman et al. (2010) SCID (DSM-IV) 28.1%  
Summary effect (95% CI) 23.1% 
(14.9–34.0)
29.9%  
(20.5–41.3)
6.7% 
(4.8–9.2)
8.8%  
(4.4–17.1)
I2 (%) 94.87 93.73 0.00 82.21
BDI: Beck Depression Inventory; CIDI: Composite International Diagnostic Interview; MINI: Mini International Neuropsychiatric Interview; SCAN: 
Schedules for Clinical Assessment in Neuropsychiatry; SCID (DSM-III-R): Structured Clinical Interview for DSM-III-R; SCID (DSM-IV): Structured 
Clinical Interview for DSM-IV.
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studies (Table 7). There was a weighted mean effect of 
75.5% (95% CI 45.6–91.8) for lifetime Axis I disorders. 
There were weighted mean effects of 47.0% (95% CI 31.0–
63.7) for any alcohol or substance use disorder, 41.1% 
(95% CI 29.1–54.2) for any alcohol use disorder, 38.6% 
(95% CI 25.7–53.4) for any mood disorder, 23.9% (95% CI 
16.3–33.8) for any anxiety disorder and 21.4% (95% CI 
12.2–34.7) for any substance (non-alcohol) use disorder. 
There was high to very high between-study heterogeneity 
for lifetime Axis I disorders.
Table 5. Prevalence of co-morbid current anxiety disorders in treatment-seeking problem gamblers.
Study
Co-
morbidity 
measure
Any anxiety 
disorder OCD
Panic 
disorder GAD PTSD Social phobia
Dannon et al. 
(2006)
Clinical 
diagnosis
9.0% 3.8% 3.8%  
Goudriaan et al.
(2010)
CIDI 17.0%  
Grant and Grosz 
(2004)
Clinical 
diagnosis
7.1% 7.1%
Grant and Kim 
(2008)
SCID  
(DSM-IV)
2.1%  
Grant et al. 
(2008)
SCID  
(DSM-IV)
11.4%  
Grant and 
Potenza (2006b)
SCID  
(DSM-IV)
8.6%  
Ibanez et al. 
(2001)
SCID  
(DSM-III-R)
4.3%  
Jimenez-Murcia 
et al. (2009)
Clinical 
diagnosis 
(DSM-IV)
10.1%  
Kausch (2003a)/ 
Kausch (2003b)
Clinical 
diagnosis
7.0% 5.3%  
Kerber et al. 
(2008)
MINI 47.5% 5.0% 27.5% 22.5%  
Ledgerwood and 
Petry (2006)
PTSD 
Checklist – 
Civilian
34.2%  
Patterson et al. 
(2006)
MINI 94.4% 50.0% 38.9% 50.0% 16.7% 50.0%
Specker et al. 
(1996)
SCID  
(DSM-III-R)
22.5% 2.5% 10.0% 5.0% 5.0% 5.0%
Tavares and 
Gentil (2007)
SCAN 27.5% 2.5%  
Tavares et al. 
(2003)
SCAN 14.3% 10.0%  
Summary effect 
(95% CI)
17.6% 
(10.8–27.3)
8.2% 
(3.4–18.6)
13.7% 
(6.7–26.0)
14.4% 
(3.9–40.8)
12.3% 
(3.4–35.7)
14.9% 
(2.0–59.8)
I2 (%) 88.44 81.86 77.42 86.98 90.58 85.61
CIDI: Composite International Diagnostic Interview; MINI: Mini International Neuropsychiatric Interview; PTSD Checklist – Civilian: Post-traumatic 
Stress Disorder Checklist – Civilian version; SCAN: Schedules for Clinical Assessment in Neuropsychiatry; SCID (DSM-III-R): Structured Clinical 
Interview for DSM-III-R; SCID (DSM-IV): Structured Clinical Interview for DSM-IV.
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Subgroup analyses
The potentially relevant sources of heterogeneity identified 
before the commencement of analysis included: (1) gam-
bling problem severity; (2) the measure of co-morbidity 
employed; (3) the type of treatment facility; and (4) the 
jurisdiction in which the study was conducted. Subgroup 
analyses were performed for the six co-morbid disorders 
that had sufficient (10 or more) primary studies available 
(any current alcohol or substance use disorder, any current 
Table 6. Prevalence of co-morbid current other Axis I disorders in treatment-seeking problem gamblers.
Study
Co-
morbidity 
measure
Intermittent 
explosive 
disorder Kleptomania
Psychotic 
disorder
Somatoform 
disorder
Adjustment 
disorder ADHD
Dannon et al. (2006) Clinical 
diagnosis
1.3%
Grall-Bronnec et al. 
(2011)
ASRS 10.5%
Grant and Kim 
(2008)
MIDI 2.1% 2.1%  
Grant and Potenza 
(2006b)
SCID  
(DSM-IV)
0% 1.0% 0%  
Grant and Potenza 
(2006b)
MIDI 4.8% 1.9%  
Ibanez et al. (2001) SCID  
(DSM-III-R)
17.4%  
Jimenez-Murcia et al.
(2009)
Clinical 
diagnosis 
(DSM-IV)
4.2%  
Kausch (2003a)/ 
Kausch (2003b)
Clinical 
diagnosis
5.3% 15.9%  
Kerber et al. (2008) MINI 10.0% 5.0% 7.5%
Ladouceur et al. 
(2006)
MCMI-III 6.0%  
Specker et al. (1995) Clinical 
diagnosis
20.0%
Specker et al. (1996) SCID  
(DSM-III-R)
2.5% 0%  
Specker et al. (1996) MIDI 7.5% 5.0%  
Stinchfield and 
Winters (2001)
Clinical 
diagnosis 
(DSM-III-R)
7.0%  
Tavares and Gentil 
(2007)
SCAN 2.5%  
Tavares et al. (2003) SCAN 3.6%  
Summary effect (95% 
CI)
4.6% 
(2.5–8.4)
2.7% 
(1.2–5.9)
4.7% 
(3.4–6.5)
3.6% 
(1.6–8.0)
9.2% 
(4.8–17.2)
9.3% 
(4.1–19.6)
I2 (%) 3.22 0.0 8.81 39.42 80.27 65.30
ASRS: Adult ADHD Self-Report Scale; MCMI-III: Millon Clinical Multiaxial Inventory-III; MIDI: Minnesota Impulsive Disorders Interview; MINI: Mini 
International Neuropsychiatric Interview; SCAN: Schedules for Clinical Assessment in Neuropsychiatry; SCID (DSM-III-R): Structured Clinical Inter-
view for DSM-III-R; SCID (DSM-IV): Structured Clinical Interview for DSM-IV.
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alcohol use disorder, any current mood disorder, current 
major depressive disorder, current bipolar disorder and any 
current anxiety disorder).
Gambling problem severity. Only alcohol use disorder and 
major depressive disorder had sufficient primary studies in 
both gambling problem severity subgroups (pathological 
gamblers and problem gamblers) to conduct subgroup anal-
yses. For alcohol use disorder, pathological gambling sam-
ples (17.3%, 95% CI 11.7–25.0) yielded statistically 
significantly lower point estimates relative to problem 
gambling samples (33.1%, 95% CI 27.1–39.7). There was 
no evidence of systematic variation in point estimates for 
major depressive disorder.
Measure of co-morbidity employed. None of the disorders 
had sufficient primary studies in both co-morbidity mea-
sure subgroups (clinician-administered interviews and self-
report questionnaires) to conduct subgroup analyses.
Type of treatment facility. Only major depressive disorder 
had sufficient primary studies in both treatment facility 
subgroups (outpatient treatment and residential treatment) 
to conduct subgroup analyses. There was no evidence of 
systematic variation in point estimates for this disorder.
Jurisdiction. All co-morbid disorders except bipolar disorder 
had sufficient primary studies in both jurisdiction sub-
groups (US and Europe) to conduct subgroup analyses. 
Prevalence estimates for alcohol use disorder from studies 
in the US (13.6%, 95% CI 7.6–23.0) were significantly 
lower than those from studies conducted in Europe (31.7%, 
95% CI 24.8–39.5). However, there was no evidence of 
systematic variation in point estimates for mood disorder, 
anxiety disorder, major depressive disorder, or alcohol or 
substance use disorder.
Risk of bias assessment
A components approach was adopted to assess risk of bias 
in this systematic review (Table 8). Measurement of co-
morbidity was the stated purpose of the study for almost 
two-thirds of the included studies (61.1%). Almost all 
(97.2%) employed a valid and reliable gambling measure, 
and most studies (86.1%) reported that they did not have 
any sponsorship from the gambling industry. Although 
most (86.1%) were observational studies of treatment in 
naturalistic settings (i.e. not clinical trials), the representa-
tiveness of the included samples was limited by only 63.9% 
reporting consecutive or random recruitment of partici-
pants. Moreover, only 19.4% of studies reported employing 
an appropriate comparison group and few studies (5.8%) 
ruled out any impact from a concurrent intervention or an 
unintended exposure that might bias results. Just under half 
of the included studies (44.4%) were classified as having a 
non-representative sampling bias (self-selected samples 
and/or clinical trials).
Sensitivity analyses
Sensitivity analyses were conducted to determine whether 
findings were robust to the inclusion of studies with non-
representative sampling biases, and involved sequentially 
limiting studies to: (1) observational studies of treatment in 
naturalistic settings (i.e. clinical trials were excluded); and 
(2) random samples or recruitment of consecutive admis-
sions (i.e. self-selected samples or studies failing to indi-
cate sampling strategies were excluded). Given the large 
number of analyses conducted, these results are available 
from the corresponding author.
Studies of naturalistic treatment. Across most types of co-
morbidity, results based on studies of naturalistic treatment 
varied minimally relative to all studies including clinical 
trials. Where salient differences were observed, they gener-
ally indicated higher estimates in analyses of naturalistic 
treatment. The largest differences were observed for: (1) 
‘any lifetime Axis I disorder’, whereby studies of naturalis-
tic treatment suggested higher estimates (k=1; 92.5%, 95% 
CI 79.2–91.8) relative to results from all studies (k=3; 
75.5%, 95% CI 45.6–0.92); and (2) ‘lifetime major depres-
sive disorder’, whereby studies of naturalistic treatment 
suggested higher estimates (k=2; 70.2%, 95% CI 59.7–
79.0) relative to results from all studies (k=3; 54.3%, 95% 
CI 21.9–83.4). In each instance, the sensitivity analyses 
were based on few studies and produced wide 95% CIs. 
Only the analyses of ‘any current impulse control disorder’ 
suggested lower estimates in studies of naturalistic treat-
ment (k=3; 6.7%, 95% CI 0.5–48.4) versus all studies (k=5; 
13.7%, 95% CI 4.2–36.1); however, the magnitude of the 
difference was small. Accordingly, it was concluded that 
the results of the review were robust to the inclusion of 
clinical trials.
Studies of random samples and consecutive admissions. Across 
most types of co-morbidity, results based on random sam-
ples or consecutive admissions varied minimally relative to 
analyses based on all studies (including self-selected sam-
ples). Where more salient differences were observed, there 
was no clear pattern of higher or lower estimates. The larg-
est increase was observed for ‘lifetime major depressive 
disorder’, whereby studies of random / consecutive samples 
suggested higher estimates (k=2; 70.2%, 95% CI 59.7–
79.0) relative to all studies (k=3; 54.3%, 95% CI 21.9–
83.4). The largest decrease was observed for ‘current social 
phobia’ (equal with GAD), whereby studies of random/
consecutive samples suggested lower estimates (k=2; 5.6%, 
95% CI 1.8–16.1) relative to results from all studies (k=3; 
14.9%, 95% CI 2.0–59.8). In each instance, the sensitivity 
analyses were based on few studies and produced wide 
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Table 8. Risk of bias assessment.
Study Purposive
Appropriate 
comparison 
group
Consecutive/ 
random 
recruitment
Naturalistic 
treatment
Concurrent 
treatment 
restriction
Valid and 
reliable 
gambling 
measure
Gambling 
industry 
sponsorship
Battersby et al. 
(2006)
Y N N Y N Y N
Breen and 
Zimmerman (2002)
N N Y Y N Y NR
Cavedini et al. (2002) N Y NR Y Y Y NR
Dannon et al. (2006) Y N NR Y N Y NR
Echeburua et al. 
(2011)
Y N Y Y N Y N
Goudriaan et al. 
(2010)
N Y NR Y N Y N
Grall-Bronnec et al. 
(2011)
Y N Y Y N Y Y
Granero et al. (2009) N N Y Y N Y N
Grant and Grosz 
(2004)
N N Y Y N Y N
Grant and Kim 
(2002)
N N Y Y N Y N
Grant and Kim 
(2008)
Y N NR N N Y N
Grant et al. (2009) Y N Y N N Y N
Grant et al. (2008) Y N Y N N Y N
Grant and Potenza 
(2006b)
Y N Y N N Y N
Ibanez et al. (2001) Y N Y Y N Y N
Jimenez-Murcia et al. 
(2009)
Y N Y Y N Y N
Kausch (2003a)/ 
Kausch (2003b)
Y N Y Y N Y N
Kausch (2004) Y Y Y Y N Y N
Kennedy et al. 
(2005)
Y N Y Y N Y N
Kerber et al. (2008) Y N N Y N Y N
Korman et al. (2008) N Y NR N N Y N
Kroeber (1992) N N NR Y N Y NR
Kruedelbach et al. 
(2006)
Y N Y Y N Y N
Ladouceur et al. 
(2006)
Y N N Y N Y N
(Continued)
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95% CIs, while the absolute magnitudes of differences 
were small. Accordingly, it was concluded that results of 
the current review were also robust to inclusion of self-
selected samples.
Discussion
Prevalence rates of co-morbid psychiatric 
disorders
This is the first systematic review and meta-analysis to 
explore the prevalence rates of co-morbid psychiatric disor-
ders in treatment-seeking problem gamblers. The findings 
from 36 studies indicated that approximately three-quarters 
of treatment-seeking problem gamblers display current and 
lifetime co-morbid Axis I disorders. The most common 
current disorders were nicotine dependence, major depres-
sive disorder, alcohol abuse and dependence, social phobia, 
GAD, panic disorder, PTSD, cannabis use disorder, ADHD, 
adjustment disorder, bipolar disorder and OCD, while the 
most common lifetime disorders were major depressive 
disorder and alcohol and substance use disorders. Unlike 
previous narrative reviews, this review used robust, replica-
ble and reliable procedures to systematically identify and 
synthesise all available evidence, including studies in 
which the investigation of co-morbidity was not the pri-
mary aim, and sheds light on the relative strength and reli-
ability of the evidence for each co-morbid psychiatric 
disorder. Although the general conclusion that treatment-
seeking problem gambling is associated with high rates of 
mood, anxiety and substance use disorders is generally 
consistent with those of available narrative reviews (Petry, 
2005; Specker et al., 1996; Westphal and Johnson, 2007), 
this review adds information about the high co-occurrence 
of problem gambling and specific disorders with less avail-
able evidence, such as social phobia, GAD, PTSD, canna-
bis use disorder, ADHD, adjustment disorder and dysthymic 
disorder.
Interestingly, the prevalence estimates derived in this 
review were not consistently higher than those derived from 
Study Purposive
Appropriate 
comparison 
group
Consecutive/ 
random 
recruitment
Naturalistic 
treatment
Concurrent 
treatment 
restriction
Valid and 
reliable 
gambling 
measure
Gambling 
industry 
sponsorship
Ledgerwood and 
Petry (2006)
Y N N Y N Y N
Lee et al. (2011)/ 
Teo et al. (2007)
Y N Y Y N Y N
Maccallum and 
Blaszczynski (2002)
Y N Y Y N Y N
Martins et al. (2004) Y N Y Y N Y N
Patterson et al. 
(2006)
Y Y N Y N Y N
Sander and Peters 
(2009)
N N Y Y N Y N
Smith et al. (2010) N N Y Y N Y N
Specker et al. 
(1995)/ Specker 
et al. (1996)
Y Y N Y N Y N
Stinchfield and 
Winters (2001)
N N Y Y N Y N
Tavares and Gentil 
(2007)
N Y Y Y Y Y N
Tavares et al. (2003) N N Y Y N Y N
Zimmerman et al. 
(2010)
N N NR Y N NR N
NR: Not reported.
Table 8. (Continued)
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a meta-analysis of community samples (Lorains et al., 
2011). This contrasts with expectations from treatment-
seeking sample selection biases (Berkson, 1946; Crockford 
and El-Guebaly, 1998) that treatment-seeking samples 
include those with the most serious gambling problems and 
the highest rates of co-morbid psychopathology (Crockford 
and El-Guebaly, 1998; Slutske et al., 2001; Specker et al., 
1996). It may suggest a paradoxical effect, whereby prob-
lem gamblers with co-morbid disorders seek treatment at 
mental health or addiction services to manage their co-mor-
bid psychopathology rather than at specialist gambling 
agencies for their gambling problems (Lorains et al., 2011; 
Winters and Kushner, 2003). This explanation is supported 
by findings that the rate of problem gambling in mental 
health, alcohol and drug, family violence and financial 
counselling services is two to 21 times higher (Dowling 
et al., 2014b, 2014c) than in the general population (Jackson 
et al., 2010). It implies that the co-morbid psychiatric condi-
tion may be of more concern than the gambling problem or 
that gamblers are more aware of their co-morbid symptoma-
tology than their gambling symptomatology. Indeed, a 
recent population study has found that approximately half of 
problem gamblers do not self-perceive even a moderate 
gambling problem (Suurvali et al., 2012). An alternative 
explanation is that the social acceptability, public awareness 
and accessibility of mental health or addiction services may 
be higher than gambling services. There may therefore be a 
need for these services to routinely screen for problem gam-
bling and have appropriate resources to assess and manage 
the gambling behaviour of problem gambling clients.
Heterogeneity in prevalence estimates  
of co-morbid psychiatric disorders
A strength of this systematic review over previous narrative 
reviews is that it was able to explore the degree to which 
prevalence estimates of co-morbidity fluctuate as a func-
tion of clinical and methodological considerations. A nota-
ble feature of the data was significant variability in the 
reported rates of many co-morbid psychiatric disorders. 
Unfortunately, although several potentially relevant meth-
odological and clinical factors that may explain the varia-
tions in these estimates were explored, no consistent 
patterns were identified. This is consistent with a meta-
analysis of community-representative samples of problem 
gamblers (Lorains et al., 2011).
However, there were a few specific findings from the 
subgroup analyses that are worth noting. The current review 
revealed significantly lower estimates for alcohol use disor-
ders in pathological gamblers than problem gamblers and 
in US studies than European studies. These findings could 
suggest that pathological gamblers with co-morbid alcohol 
use disorders are more likely to seek assistance at alcohol 
treatment services than at gambling agencies (Lorains 
et al., 2011; Westphal and Johnson, 2007) and that problem 
gamblers with alcohol use disorders in the US may be more 
likely to seek treatment for alcohol use problems than gam-
bling problems compared to their European counterparts. 
Alternatively, of course, the findings relating to jurisdic-
tional variances could reflect differences in the provision of 
gambling treatment services across the US and Europe.
As more studies become available and reporting 
improves, future updates of this review may consider the 
effect of these and other sample characteristics (such as gen-
der composition of the sample, problematic gambling activ-
ity), measurement factors (such as the method and quality of 
problem gambling and comorbidity measurement), treat-
ment factors (such as type of treatment delivered) or other 
methodological considerations (such as sample size and 
year of publication). Subgroup analysis of other methodo-
logical issues considered in the risk of bias assessment could 
also be analysed as sources of variation that could be 
included in future updates of this review, such as the purpo-
sive nature of the co-morbidity measurement, the influence 
of sponsorship from the gambling industry, the use of a 
comparison group, and concurrent treatment restriction.
Limitations of the available evidence base
Several limitations of the evidence on which the review is 
based are noted. First, although most studies were observa-
tional studies of treatment in naturalistic settings, only two-
thirds of studies reported consecutive or random recruitment 
of participants. Just under half of the included studies were 
classified as having a non-representative sampling bias as 
evidenced by the inclusion of self-selected samples and/or 
clinical trials. Although a higher degree of sample repre-
sentativeness is necessary in future research, the sensitivity 
analyses conducted in the current systematic review sug-
gested that the identified prevalence estimates were robust 
to the inclusion of clinical trials and self-selected samples.
Second, although all cross-sectional, case-control and 
cohort studies that examined the prevalence of psychiatric 
conditions in treatment-seeking problem gamblers were 
included, less than 20% of studies included healthy control 
groups. The failure to employ these groups do not allow for 
conclusions regarding the presence of a psychiatric co- 
morbidity between the problem gambling group and their 
non-gambling counterparts. Moreover, most studies were 
unable to rule out any impact from a concurrent interven-
tion that might bias their results. Future research incorpo-
rating healthy control groups and exclusion criteria relating 
to concurrent interventions will enhance the rigour of future 
research in this area.
Third, most samples were treated in outpatient or resi-
dential facilities, with studies delivered in online or tele-
phone settings predominantly excluded on the basis of 
employing non-standardised measures of psychiatric co-
morbidity or clinical characteristics that are not listed as 
diagnostic conditions in the DSM-IV. Similarly, while 
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studies exploring self-help treatments, Gamblers 
Anonymous and pharmacological treatments were not 
excluded from this review, very few studies administering 
these treatments were included. Given the increased acces-
sibility and confidentiality provided by telephone counsel-
ling services, web-based counselling services and self-help 
interventions (Dowling et al., 2014b, 2014c; Rodda et al., 
2013a, 2013b, 2015), it will be important for future studies 
to evaluate the psychiatric co-morbidity of these treatment-
seeking gamblers using standardised instruments.
Fourth, the cross-sectional nature of the studies reviewed 
precludes an explication of the temporal or causal relation-
ship between problem gambling and these co-morbid condi-
tions. Future research exploring the onset and pattern of 
psychiatric disorders and problem gambling using prospec-
tive study designs is therefore needed (Westphal and Johnson, 
2007). The prevalence estimates identified in this review 
must also be interpreted in the context of an emerging litera-
ture indicating that a substantial proportion of treatment- 
seeking problem gamblers have multiple co-morbid condi-
tions (Ibanez et al., 2001; Kerber et al., 2008; Kruedelbach 
et al., 2006; Westphal and Johnson, 2007). Because failure to 
control for other disorders may produce inflated rates of psy-
chiatric co-morbidity (Bagby et al., 2008), research control-
ling for multiple co-occurring disorders or using 
multi-morbidity coefficients (Batstra et al., 2002) is required.
Finally, there are several other limitations of the existing 
evidence base that are important in determining the direction 
of future research. The sample sizes of the included studies 
are generally small and many do not report important charac-
teristics of the study, such as the problematic gambling activ-
ity of the participants, the type of treatment facility or the 
type of treatment delivered. Moreover, although the larger 
number of problem gamblers in treatment-seeking samples 
allows for the investigation of lower prevalence co-morbid 
disorders (Westphal and Johnson, 2007), there remain many 
classes of Axis I psychiatric conditions in the DSM-IV that 
were not explored by sufficient studies to be included in the 
review, such as cognitive disorders, dissociative disorders, 
eating disorders, factitious disorders, sexual and gender 
identity disorders, and sleep disorders. There were also insuf-
ficient studies investigating the prevalence of specific disor-
ders within classes that were well-represented in the available 
literature, such as anxiety disorders (e.g. specific phobia, 
acute stress disorder), substance use disorders (e.g. opioid-
related disorders, cocaine-related disorders) and impulse 
control disorders (e.g. pyromania, trichotillomania). Future 
studies using large samples and rigorous reporting protocols 
are required to investigate the prevalence of these less com-
mon psychiatric disorders.
Clinical implications for practice and research
Although there are some issues around the precision of 
the findings in the current review, it is clear that 
treatment-seeking problem gamblers report generally high 
rates of psychiatric co-morbidity. The findings of this 
review therefore highlight the need to undertake systematic 
and routine screening and comprehensive assessment of co-
occurring psychiatric disorders in individuals seeking treat-
ment for gambling problems (Dowling et al., 2014b, 2014c; 
Petry, 2005; Westphal and Johnson, 2007). This can be 
achieved through comprehensive screening for multiple 
psychiatric co-morbid disorders or targeted screening for 
prevalent psychiatric disorders such as alcohol and sub-
stance use disorders, mood disorders and anxiety disorders 
(Westphal and Johnson, 2007). Clients who screen posi-
tively for co-morbid problems will require more extensive 
diagnostic assessments, an exploration of the ways in which 
the comorbidity is associated with the gambling problem, 
and identification of therapeutic needs.
The findings of this review also underscore the need to 
develop individually tailored case formulations, treatment 
plans, treatment objectives and individualised intervention 
approaches for problem gamblers with co-morbid psychiat-
ric conditions. Such recognition of psychiatric co-morbidity 
could serve to maximize treatment response, enhance client 
satisfaction, reduce attrition and lower treatment costs 
(Ladouceur et al., 2006). There is also a need for an appro-
priate clinical response by specialist gambling agencies, 
such as appropriate referral pathways or a workforce with 
adequate skills to appropriately manage these disorders 
(Petry, 2005; Specker et al., 1996 Westphal and Johnson, 
2007). The presence of high levels of psychiatric co-mor-
bidity suggests that a multimodal, stepped care approach to 
gambling treatment may be appropriate, whereby treatment 
intensity increases with increasing client needs. Such a 
stepped care approach involves a treatment network that 
encompasses a continuum of integrated services delivering 
a broad spectrum of treatment from minimally restrictive to 
increasingly intensive approaches (Marotta, 2003).
Despite their obvious importance, the implications of 
co-morbid psychiatric disorders for treatment have received 
little research attention. Although there is some evidence 
that psychiatric co-morbidity is associated with poorer out-
comes and higher attrition rates (Echeburua et al., 2001; 
Hodgins and El-Guebaly, 2010; Milton et al., 2002), few 
studies have applied targeted pharmacological (Black, 
2004; Grant and Potenza, 2006a; Hollander et al., 2005) or 
psychological (Korman et al., 2008) treatments to sub-
groups of problem gamblers with co-occurring psychiatric 
co-morbidity. Further research is required to evaluate the 
efficacy of interventions specifically designed for these 
subgroups of problem gamblers.
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